However, the analysis will to some extent underestimate the cost-effectiveness of using G-CSF because we only included hospital admissions due to febrile neutropenic events but there will be patients with infection who require treatment that are not hospitalised and we did not include the cost of having a treatment delay due to neutropenia. This evidence concerns the gene CSF3 and neutropenia.